Clough Capital Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Clough Capital Partners’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-52,902	Closed	-$4.35M	–	130
2022 Q1	$4.35M	Sell	52,902 -47,553	-47%	-$4.86M	0.33%	68
2021 Q4	$14.7M	Buy	100,455 +51,100	+104%	+$7.93M	0.99%	32
2021 Q3	$8.73M	Sell	49,355 -49,360	-50%	-$7.94M	0.53%	57
2021 Q2	$15.9M	Buy	98,715 +83,410	+545%	+$13.4M	0.87%	49
2021 Q1	$2.62M	Sell	15,305 -400	-3%	-$79.2K	0.12%	93
2020 Q4	$3.45M	Sell	15,705 -52,465	-77%	-$11.3M	0.25%	78
2020 Q3	$11.3M	Sell	68,170 -61,790	-48%	-$8.46M	0.81%	46
2020 Q2	$14.8M	Buy	129,960 +21,660	+20%	+$2.1M	1.45%	19
2020 Q1	$8.32M	Buy	+108,300	New	+$9.71M	0.83%	37

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Clough Capital Partners's MRTX Position: Q2 2022 in Review

Clough Capital Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 52,902 shares — an estimated $4.35M sold.

Clough Capital Partners first reported a position in MRTX in Q1 2020 and held it in 9 quarters. The position peaked at $15.9M in Q2 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Clough Capital Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Clough Capital Partners sold 52,902 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $4.35M.
Clough Capital Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
Clough Capital Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $15.9M in Q2 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Clough Capital Partners's 13F filing for Q2 2022, filed 16 Aug 2022.